Novo Nordisk acquires Embark Biotech, including its lead asset targeting obesity and other cardiometabolic diseases. | More News

Novo Nordisk acquires Embark Biotech, including its lead asset targeting obesity and other cardiometabolic diseases.

Related Keywords

Copenhagen ,Køavn ,Denmark ,Zach Gerhart Hines ,Jakob Bondo Hansen ,Novo Nordisk ,Obesity Research At Novo Nordisk ,Bioinnovation Institute ,Novo Nordisk Foundation Center ,Novo Nordisk Foundation ,Novo Holdings ,Innovation Fund Denmark ,Metabolic Research ,University Of Copenhagen ,Venture House Program ,Embark Biotech ,Denmarki August ,Embark Laboratories ,Vice President ,Obesity Research ,Chief Technology Officer ,Innovation Fund ,Basic Metabolic Research ,Associate Professor Zach Gerhart Hines ,Professor Thue ,Venture House ,Business ,Strategy ,Icensing ,Collaboration ,Merger Amp Acquisition ,Meal ,Agreement ,Sales ,Financial ,Management ,